Nautilus, Inc. NLS
0.82 +0.82
Day range unavailable
52-week range unavailable
News
seekingalpha.com Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch NAUT is extending Voyager from tau into oncology, which I think will give it more applications for its targeted proteoform platform. NAUT also has research collaborations and SEEDS participation. In…
marketbeat.com Nautilus Biotechnology Q3 Earnings Call Highlights Nautilus Biotechnology NASDAQ: NAUT reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming…
globenewswire.com Nautilus Biotechnology Reports Third Quarter 2026 Financial Results SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the…
globenewswire.com Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and…
globenewswire.com Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report…
thenewswire.com Red Canyon Initiates First Diamond Drill Program on its Nautilus Copper-Gold Target Vancouver, British Columbia - TheNewswire - October 8, 2026: Red Canyon Resources Ltd. (“Red Canyon” or the “Company”) (CSE: REDC | OTCQB: REDRF | Frankfurt: I9I) is pleased to announce that it has…
globenewswire.com Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method…
businesswire.com Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) has acquired assets from Tennessee-based Nautilus Pharmacy.
seekingalpha.com Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access…
marketbeat.com Nautilus Biotechnology Q2 Earnings Call Highlights Nautilus Biotechnology NASDAQ: NAUT said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its…
globenewswire.com Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the…
globenewswire.com Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026 SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report…
globenewswire.com Nautilus Biotechnology Reports First Quarter 2026 Financial Results SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the…
globenewswire.com Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform • Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages…
globenewswire.com PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA…
globenewswire.com Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company…
globenewswire.com Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging • Buck Institute's deployment of Nautilus' instrument generates tau proteoform data, providing external validation of the company's next-generation single-molecule proteomics platform • Joint…
prnewswire.com NLS Pharmaceutics Ltd. and Kadimastem Ltd. Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/…
prnewswire.com NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs Supported by Solid Cash Position and Strategic Funding Outlook ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS…
prnewswire.com NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger ZURICH , Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous…
benzinga.com 12 Consumer Discretionary Stocks Moving In Friday's Intraday Session 
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 150 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 155 companies set new 52-week lows.- benzinga.com Earnings Scheduled For August 9, 2023 Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $0.96 per share on revenue of $18.11 billion.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 70 companies achieved new lows for the year.
benzinga.com Earnings Scheduled For May 23, 2023 Companies Reporting Before The Bell • ATRenew (NYSE:RERE) is estimated to report quarterly earnings at $0.03 per share on revenue of $405.22 million.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 164 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 100 companies set new 52-week lows.
benzinga.com Earnings Scheduled For February 9, 2023 Companies Reporting Before The Bell • AstraZeneca (NASDAQ:AZN) is expected to report quarterly earnings at $0.67 per share on revenue of $11.21 billion.- benzinga.com Earnings Scheduled For November 9, 2022 Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly earnings at $0.11 per share on revenue of $103.46 million.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
benzinga.com 12 Consumer Discretionary Stocks Moving In Monday's After-Market Session Gainers
benzinga.com Earnings Scheduled For August 9, 2022 Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 588 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 340 companies made new 52-week lows.
- benzinga.com 71 Biggest Movers From Yesterday Gainers CynergisTek, Inc. (NYSE: CTEK) shares surged 100% to close at $1.18 on Tuesday after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7…
- benzinga.com 12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 540 companies set new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022 Upgrades
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's morning session, 234 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 147 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 166 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Earnings Scheduled For February 9, 2022 Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.